25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

iBio, Inc. Common Stock
Buy, Hold or Sell?

Let's analyze iBio, Inc. Common Stock together

I guess you are interested in iBio, Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of iBio, Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about iBio, Inc. Common Stock

I send you an email if I find something interesting about iBio, Inc. Common Stock.

1. Quick Overview

1.1. Quick analysis of iBio, Inc. Common Stock (30 sec.)










1.2. What can you expect buying and holding a share of iBio, Inc. Common Stock? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.52
Expected worth in 1 year
$2.03
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$0.51
Return On Investment
9.3%

For what price can you sell your share?

Current Price per Share
$5.54
Expected price per share
$3.15 - $8.568
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of iBio, Inc. Common Stock (5 min.)




Live pricePrice per Share (EOD)
$5.54
Intrinsic Value Per Share
$-26.38 - $35.35
Total Value Per Share
$-24.86 - $36.87

2.2. Growth of iBio, Inc. Common Stock (5 min.)




Is iBio, Inc. Common Stock growing?

Current yearPrevious yearGrowGrow %
How rich?$13.8m$13.7m$5.6m29.1%

How much money is iBio, Inc. Common Stock making?

Current yearPrevious yearGrowGrow %
Making money-$4.8m-$6.5m$1.7m36.3%
Net Profit Margin-1,656.6%-2,873.0%--

How much money comes from the company's main activities?

2.3. Financial Health of iBio, Inc. Common Stock (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#571 / 917

Most Revenue
#634 / 917

Most Profit
#399 / 917

Most Efficient
#748 / 917
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of iBio, Inc. Common Stock?

Welcome investor! iBio, Inc. Common Stock's management wants to use your money to grow the business. In return you get a share of iBio, Inc. Common Stock.

First you should know what it really means to hold a share of iBio, Inc. Common Stock. And how you can make/lose money.

Speculation

The Price per Share of iBio, Inc. Common Stock is $5.54. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of iBio, Inc. Common Stock.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in iBio, Inc. Common Stock, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.52. Based on the TTM, the Book Value Change Per Share is $0.13 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.26 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of iBio, Inc. Common Stock.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.48-8.6%-0.53-9.5%-0.71-12.9%-0.96-17.4%-0.73-13.2%
Usd Book Value Change Per Share-0.42-7.6%0.132.3%-0.26-4.8%0.081.4%0.010.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.42-7.6%0.132.3%-0.26-4.8%0.081.4%0.010.2%
Usd Price Per Share2.45-2.71-1.09-1.38-0.98-
Price to Earnings Ratio-1.28--1.52--0.38-1.80-0.69-
Price-to-Total Gains Ratio-5.80--3.64--5.11--5.97--2.71-
Price to Book Ratio1.61-1.29-0.76-0.86-0.53-
Price-to-Total Gains Ratio-5.80--3.64--5.11--5.97--2.71-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.54
Number of shares180
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.130.08
Usd Total Gains Per Share0.130.08
Gains per Quarter (180 shares)23.1414.20
Gains per Year (180 shares)92.5456.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10938305747
201851760114104
302782690170161
403703620227218
504634550284275
605555480341332
706486410398389
807407340454446
908338270511503
1009259200568560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.039.00.02.5%3.067.00.04.3%
Book Value Change Per Share1.03.00.025.0%1.010.01.08.3%5.014.01.025.0%12.025.03.030.0%21.041.08.030.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.070.00.0%
Total Gains per Share1.03.00.025.0%1.010.01.08.3%5.014.01.025.0%12.025.03.030.0%21.041.08.030.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of iBio, Inc. Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.4220.129-429%-0.263-38%0.079-635%0.012-3667%
Book Value Per Share--1.5212.129-29%1.510+1%5.112-70%3.147-52%
Current Ratio--1.7592.725-35%1.115+58%6.150-71%5.692-69%
Debt To Asset Ratio--0.3600.349+3%0.654-45%0.438-18%0.530-32%
Debt To Equity Ratio--0.5610.577-3%1.946-71%1.315-57%2.097-73%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--21600855.00022566959.000-4%-11782943.338+155%32948631.523-34%12913704.182+67%
Eps---0.478-0.528+11%-0.712+49%-0.962+101%-0.733+53%
Ev To Ebitda Ratio---1.341-1.817+35%0.642-309%-1.223-9%-0.409-70%
Ev To Sales Ratio--27.001infnan%inf+inf%nannan%nannan%
Free Cash Flow Per Share---0.424-0.446+5%-0.525+24%-0.802+89%-0.568+34%
Free Cash Flow To Equity Per Share---0.4400.038-1249%-0.233-47%-0.117-73%-0.050-89%
Gross Profit Margin--1.0001.037-4%1.0000%1.007-1%1.0040%
Intrinsic Value_10Y_max--35.349--------
Intrinsic Value_10Y_min---26.376--------
Intrinsic Value_1Y_max---1.433--------
Intrinsic Value_1Y_min---3.011--------
Intrinsic Value_3Y_max---0.514--------
Intrinsic Value_3Y_min---8.782--------
Intrinsic Value_5Y_max--4.976--------
Intrinsic Value_5Y_min---14.218--------
Market Cap50623966.000+56%22387855.00024763709.000-10%9968306.663+125%27111631.523-17%16203979.182+38%
Net Profit Margin---21.820-16.566-24%-28.730+32%-64.123+194%-46.236+112%
Operating Margin---21.535-9.935-54%-24.900+16%-43.907+104%-35.127+63%
Operating Ratio--23.0959.831+135%27.015-15%45.879-50%47.363-51%
Pb Ratio3.643+56%1.6111.288+25%0.757+113%0.864+87%0.533+203%
Pe Ratio-2.900-126%-1.283-1.524+19%-0.380-70%1.802-171%0.686-287%
Price Per Share5.540+56%2.4502.710-10%1.091+125%1.376+78%0.978+151%
Price To Free Cash Flow Ratio-3.270-126%-1.446-1.575+9%-0.586-59%-1.422-2%-1.009-30%
Price To Total Gains Ratio-13.118-126%-5.801-3.641-37%-5.107-12%-5.966+3%-2.710-53%
Quick Ratio--1.4922.377-37%0.210+611%6.481-77%5.792-74%
Return On Assets---0.201-0.174-13%-0.171-15%-0.157-22%-0.136-32%
Return On Equity---0.314-0.258-18%-0.521+66%-0.380+21%-0.409+30%
Total Gains Per Share---0.4220.129-429%-0.263-38%0.079-635%0.012-3667%
Usd Book Value--13895000.00019459000.000-29%13794000.000+1%49359900.000-72%30079200.000-54%
Usd Book Value Change Per Share---0.4220.129-429%-0.263-38%0.079-635%0.012-3667%
Usd Book Value Per Share--1.5212.129-29%1.510+1%5.112-70%3.147-52%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--21600855.00022566959.000-4%-11782943.338+155%32948631.523-34%12913704.182+67%
Usd Eps---0.478-0.528+11%-0.712+49%-0.962+101%-0.733+53%
Usd Free Cash Flow---3870000.000-4075750.000+5%-4798250.000+24%-7547850.000+95%-5302100.000+37%
Usd Free Cash Flow Per Share---0.424-0.446+5%-0.525+24%-0.802+89%-0.568+34%
Usd Free Cash Flow To Equity Per Share---0.4400.038-1249%-0.233-47%-0.117-73%-0.050-89%
Usd Market Cap50623966.000+56%22387855.00024763709.000-10%9968306.663+125%27111631.523-17%16203979.182+38%
Usd Price Per Share5.540+56%2.4502.710-10%1.091+125%1.376+78%0.978+151%
Usd Profit---4364000.000-4825750.000+11%-6576000.000+51%-9762800.000+124%-6618325.000+52%
Usd Revenue--200000.00093750.000+113%12500.000+1500%358300.000-44%308825.000-35%
Usd Total Gains Per Share---0.4220.129-429%-0.263-38%0.079-635%0.012-3667%
 EOD+5 -3MRQTTM+10 -27YOY+26 -115Y+16 -2110Y+19 -18

3.3 Fundamental Score

Let's check the fundamental score of iBio, Inc. Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.900
Price to Book Ratio (EOD)Between0-13.643
Net Profit Margin (MRQ)Greater than0-21.820
Operating Margin (MRQ)Greater than0-21.535
Quick Ratio (MRQ)Greater than11.492
Current Ratio (MRQ)Greater than11.759
Debt to Asset Ratio (MRQ)Less than10.360
Debt to Equity Ratio (MRQ)Less than10.561
Return on Equity (MRQ)Greater than0.15-0.314
Return on Assets (MRQ)Greater than0.05-0.201
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of iBio, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.233
Ma 20Greater thanMa 504.495
Ma 50Greater thanMa 1003.500
Ma 100Greater thanMa 2003.049
OpenGreater thanClose5.580
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About iBio, Inc. Common Stock

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-03-10 09:09:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit iBio, Inc. Common Stock earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare iBio, Inc. Common Stock to the Biotechnology industry mean.
  • A Net Profit Margin of -2,182.0% means that $-21.82 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of iBio, Inc. Common Stock:

  • The MRQ is -2,182.0%. The company is making a huge loss. -2
  • The TTM is -1,656.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,182.0%TTM-1,656.6%-525.4%
TTM-1,656.6%YOY-2,873.0%+1,216.4%
TTM-1,656.6%5Y-6,412.3%+4,755.6%
5Y-6,412.3%10Y-4,623.6%-1,788.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,182.0%-99.7%-2,082.3%
TTM-1,656.6%-203.8%-1,452.8%
YOY-2,873.0%-199.6%-2,673.4%
5Y-6,412.3%-328.9%-6,083.4%
10Y-4,623.6%-481.7%-4,141.9%
4.3.1.2. Return on Assets

Shows how efficient iBio, Inc. Common Stock is using its assets to generate profit.

  • Above 5% is considered healthy but always compare iBio, Inc. Common Stock to the Biotechnology industry mean.
  • -20.1% Return on Assets means that iBio, Inc. Common Stock generated $-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of iBio, Inc. Common Stock:

  • The MRQ is -20.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.1%TTM-17.4%-2.7%
TTM-17.4%YOY-17.1%-0.4%
TTM-17.4%5Y-15.7%-1.7%
5Y-15.7%10Y-13.6%-2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.1%-12.5%-7.6%
TTM-17.4%-12.3%-5.1%
YOY-17.1%-11.8%-5.3%
5Y-15.7%-13.2%-2.5%
10Y-13.6%-15.1%+1.5%
4.3.1.3. Return on Equity

Shows how efficient iBio, Inc. Common Stock is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare iBio, Inc. Common Stock to the Biotechnology industry mean.
  • -31.4% Return on Equity means iBio, Inc. Common Stock generated $-0.31 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of iBio, Inc. Common Stock:

  • The MRQ is -31.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-31.4%TTM-25.8%-5.6%
TTM-25.8%YOY-52.1%+26.3%
TTM-25.8%5Y-38.0%+12.2%
5Y-38.0%10Y-40.9%+2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-31.4%-15.9%-15.5%
TTM-25.8%-16.6%-9.2%
YOY-52.1%-15.2%-36.9%
5Y-38.0%-18.9%-19.1%
10Y-40.9%-20.4%-20.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of iBio, Inc. Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient iBio, Inc. Common Stock is operating .

  • Measures how much profit iBio, Inc. Common Stock makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare iBio, Inc. Common Stock to the Biotechnology industry mean.
  • An Operating Margin of -2,153.5% means the company generated $-21.54  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of iBio, Inc. Common Stock:

  • The MRQ is -2,153.5%. The company is operating very inefficient. -2
  • The TTM is -993.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,153.5%TTM-993.5%-1,160.0%
TTM-993.5%YOY-2,490.0%+1,496.5%
TTM-993.5%5Y-4,390.7%+3,397.2%
5Y-4,390.7%10Y-3,512.7%-878.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,153.5%-208.0%-1,945.5%
TTM-993.5%-308.8%-684.7%
YOY-2,490.0%-208.2%-2,281.8%
5Y-4,390.7%-367.6%-4,023.1%
10Y-3,512.7%-480.4%-3,032.3%
4.3.2.2. Operating Ratio

Measures how efficient iBio, Inc. Common Stock is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 23.10 means that the operating costs are $23.10 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of iBio, Inc. Common Stock:

  • The MRQ is 23.095. The company is inefficient in keeping operating costs low. -1
  • The TTM is 9.831. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ23.095TTM9.831+13.264
TTM9.831YOY27.015-17.184
TTM9.8315Y45.879-36.048
5Y45.87910Y47.363-1.484
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.0952.117+20.978
TTM9.8313.151+6.680
YOY27.0153.190+23.825
5Y45.8794.701+41.178
10Y47.3636.433+40.930
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of iBio, Inc. Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if iBio, Inc. Common Stock is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.76 means the company has $1.76 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of iBio, Inc. Common Stock:

  • The MRQ is 1.759. The company is able to pay all its short-term debts. +1
  • The TTM is 2.725. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.759TTM2.725-0.966
TTM2.725YOY1.115+1.611
TTM2.7255Y6.150-3.424
5Y6.15010Y5.692+0.458
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7593.609-1.850
TTM2.7253.858-1.133
YOY1.1154.488-3.373
5Y6.1505.973+0.177
10Y5.6926.280-0.588
4.4.3.2. Quick Ratio

Measures if iBio, Inc. Common Stock is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare iBio, Inc. Common Stock to the Biotechnology industry mean.
  • A Quick Ratio of 1.49 means the company can pay off $1.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of iBio, Inc. Common Stock:

  • The MRQ is 1.492. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 2.377. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.492TTM2.377-0.885
TTM2.377YOY0.210+2.167
TTM2.3775Y6.481-4.104
5Y6.48110Y5.792+0.689
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4923.024-1.532
TTM2.3773.308-0.931
YOY0.2104.370-4.160
5Y6.4815.954+0.527
10Y5.7926.492-0.700
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of iBio, Inc. Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of iBio, Inc. Common Stock assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare iBio, Inc. Common Stock to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.36 means that iBio, Inc. Common Stock assets are financed with 36.0% credit (debt) and the remaining percentage (100% - 36.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of iBio, Inc. Common Stock:

  • The MRQ is 0.360. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.349. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.360TTM0.349+0.010
TTM0.349YOY0.654-0.304
TTM0.3495Y0.438-0.089
5Y0.43810Y0.530-0.092
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3600.341+0.019
TTM0.3490.342+0.007
YOY0.6540.310+0.344
5Y0.4380.363+0.075
10Y0.5300.384+0.146
4.5.4.2. Debt to Equity Ratio

Measures if iBio, Inc. Common Stock is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare iBio, Inc. Common Stock to the Biotechnology industry mean.
  • A Debt to Equity ratio of 56.1% means that company has $0.56 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of iBio, Inc. Common Stock:

  • The MRQ is 0.561. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.577. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.561TTM0.577-0.015
TTM0.577YOY1.946-1.369
TTM0.5775Y1.315-0.738
5Y1.31510Y2.097-0.782
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5610.387+0.174
TTM0.5770.430+0.147
YOY1.9460.391+1.555
5Y1.3150.451+0.864
10Y2.0970.495+1.602
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings iBio, Inc. Common Stock generates.

  • Above 15 is considered overpriced but always compare iBio, Inc. Common Stock to the Biotechnology industry mean.
  • A PE ratio of -1.28 means the investor is paying $-1.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of iBio, Inc. Common Stock:

  • The EOD is -2.900. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.283. Based on the earnings, the company is expensive. -2
  • The TTM is -1.524. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.900MRQ-1.283-1.618
MRQ-1.283TTM-1.524+0.242
TTM-1.524YOY-0.380-1.144
TTM-1.5245Y1.802-3.326
5Y1.80210Y0.686+1.116
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.900-2.175-0.725
MRQ-1.283-2.706+1.423
TTM-1.524-3.275+1.751
YOY-0.380-3.402+3.022
5Y1.802-6.326+8.128
10Y0.686-6.808+7.494
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of iBio, Inc. Common Stock:

  • The EOD is -3.270. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.446. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.575. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.270MRQ-1.446-1.824
MRQ-1.446TTM-1.575+0.129
TTM-1.575YOY-0.586-0.989
TTM-1.5755Y-1.422-0.154
5Y-1.42210Y-1.009-0.413
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.270-2.977-0.293
MRQ-1.446-3.670+2.224
TTM-1.575-3.936+2.361
YOY-0.586-4.315+3.729
5Y-1.422-8.475+7.053
10Y-1.009-9.317+8.308
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of iBio, Inc. Common Stock is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.61 means the investor is paying $1.61 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of iBio, Inc. Common Stock:

  • The EOD is 3.643. Based on the equity, the company is fair priced.
  • The MRQ is 1.611. Based on the equity, the company is underpriced. +1
  • The TTM is 1.288. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.643MRQ1.611+2.032
MRQ1.611TTM1.288+0.324
TTM1.288YOY0.757+0.531
TTM1.2885Y0.864+0.424
5Y0.86410Y0.533+0.331
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.6431.892+1.751
MRQ1.6112.177-0.566
TTM1.2882.392-1.104
YOY0.7572.461-1.704
5Y0.8643.815-2.951
10Y0.5334.539-4.006
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of iBio, Inc. Common Stock.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets21,697
Total Liabilities7,802
Total Stockholder Equity13,895
 As reported
Total Liabilities 7,802
Total Stockholder Equity+ 13,895
Total Assets = 21,697

Assets

Total Assets21,697
Total Current Assets8,285
Long-term Assets13,412
Total Current Assets
Cash And Cash Equivalents 7,015
Net Receivables 13
Other Current Assets 1,257
Total Current Assets  (as reported)8,285
Total Current Assets  (calculated)8,285
+/-0
Long-term Assets
Property Plant Equipment 5,824
Intangible Assets 6,108
Long-term Assets Other 1,480
Long-term Assets  (as reported)13,412
Long-term Assets  (calculated)13,412
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,709
Long-term Liabilities3,093
Total Stockholder Equity13,895
Total Current Liabilities
Short-term Debt 667
Short Long Term Debt 237
Accounts payable 614
Other Current Liabilities 3,428
Total Current Liabilities  (as reported)4,709
Total Current Liabilities  (calculated)4,946
+/- 237
Long-term Liabilities
Long term Debt 643
Capital Lease Obligations Min Short Term Debt2,450
Long-term Liabilities  (as reported)3,093
Long-term Liabilities  (calculated)3,093
+/-0
Total Stockholder Equity
Common Stock9
Retained Earnings -322,200
Other Stockholders Equity 336,086
Total Stockholder Equity (as reported)13,895
Total Stockholder Equity (calculated)13,895
+/-0
Other
Capital Stock9
Cash and Short Term Investments 7,015
Common Stock Shares Outstanding 9,132
Liabilities and Stockholders Equity 21,697
Net Debt -3,898
Net Invested Capital 14,775
Net Working Capital 3,576
Property Plant and Equipment Gross 7,688
Short Long Term Debt Total 3,117



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-30
> Total Assets 
0
0
0
3,549
6,817
5,701
5,227
4,930
7,450
7,912
5,477
4,930
4,930
10,416
8,050
7,336
5,577
5,020
10,656
9,765
9,765
6,805
4,981
9,354
7,335
9,618
8,214
6,494
6,657
11,042
11,446
12,494
12,494
9,416
50,665
51,600
51,600
44,188
40,698
36,010
33,433
34,840
31,034
43,083
42,896
40,303
35,674
30,586
35,164
36,384
42,220
94,189
94,189
145,406
142,697
146,968
143,739
126,448
115,370
99,406
99,406
51,800
44,386
41,207
37,678
34,022
50,154
28,734
24,517
21,697
21,69724,51728,73450,15434,02237,67841,20744,38651,80099,40699,406115,370126,448143,739146,968142,697145,40694,18994,18942,22036,38435,16430,58635,67440,30342,89643,08331,03434,84033,43336,01040,69844,18851,60051,60050,6659,41612,49412,49411,44611,0426,6576,4948,2149,6187,3359,3544,9816,8059,7659,76510,6565,0205,5777,3368,05010,4164,9304,9305,4777,9127,4504,9305,2275,7016,8173,549000
   > Total Current Assets 
0
0
0
168
3,366
2,122
1,667
1,266
3,654
4,060
1,550
1,026
1,026
6,554
4,229
4,300
2,529
1,938
7,678
6,900
6,900
3,995
2,211
6,635
4,645
6,940
5,532
3,913
4,121
8,562
9,044
10,121
10,121
7,201
22,723
23,906
23,906
16,748
12,984
8,572
6,382
7,823
3,986
16,285
16,335
13,969
9,586
4,808
2,361
4,007
10,304
61,748
61,748
110,882
107,203
104,597
89,817
67,496
60,316
45,070
45,070
38,235
27,093
26,259
23,022
19,699
36,139
15,672
11,705
8,285
8,28511,70515,67236,13919,69923,02226,25927,09338,23545,07045,07060,31667,49689,817104,597107,203110,88261,74861,74810,3044,0072,3614,8089,58613,96916,33516,2853,9867,8236,3828,57212,98416,74823,90623,90622,7237,20110,12110,1219,0448,5624,1213,9135,5326,9404,6456,6352,2113,9956,9006,9007,6781,9382,5294,3004,2296,5541,0261,0261,5504,0603,6541,2661,6672,1223,366168000
       Cash And Cash Equivalents 
0
0
0
19
3,019
1,718
1,417
1,039
3,377
3,001
1,495
910
910
5,769
3,836
2,843
1,523
623
6,724
5,624
5,624
2,819
1,527
4,414
3,444
5,678
4,333
3,590
3,486
7,363
8,080
9,494
9,494
6,732
21,893
23,014
23,014
16,329
12,422
8,088
5,916
7,310
3,398
15,934
16,010
13,361
9,037
4,421
2,103
3,637
10,040
55,112
55,112
91,252
84,627
77,404
62,820
39,205
33,767
22,676
22,676
3,696
6,562
4,301
1,461
2,788
6,216
14,210
11,038
7,015
7,01511,03814,2106,2162,7881,4614,3016,5623,69622,67622,67633,76739,20562,82077,40484,62791,25255,11255,11210,0403,6372,1034,4219,03713,36116,01015,9343,3987,3105,9168,08812,42216,32923,01423,01421,8936,7329,4949,4948,0807,3633,4863,5904,3335,6783,4444,4141,5272,8195,6245,6246,7246231,5232,8433,8365,7699109101,4953,0013,3771,0391,4171,7183,01919000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,010
16,395
19,296
19,570
19,453
18,172
14,813
10,845
10,845
5,929
0
0
0
0
0
0
0
0
000000005,92910,84510,84514,81318,17219,45319,57019,29616,3956,0100000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
105
305
327
190
210
206
15
9
47
47
60
0
344
320
234
372
351
351
390
390
1,007
1,007
1,007
1,007
205
555
922
666
445
445
217
454
606
606
100
128
175
260
136
181
75
119
212
117
97
75
224
75
5,624
5,624
232
388
5,526
5,307
5,211
6,104
1,000
6,100
7,739
1,242
204
0
1,750
14,104
713
0
13
13071314,1041,75002041,2427,7396,1001,0006,1045,2115,3075,5263882325,6245,624752247597117212119751811362601751281006066064542174454456669225552051,0071,0071,0071,0073903903513513722343203440604747915206210190327305105000
       Other Current Assets 
0
0
0
44
43
77
60
17
71
1,044
46
68
68
725
393
349
389
284
377
924
240
53
294
31
194
255
192
8
80
277
298
182
17
252
318
2,384
264
292
374
283
206
377
407
276
206
396
432
290
183
146
189
34,547
214
1,932
2,460
2,070
1,650
2,922
2,349
5,100
-82
414
921
664
451
16,055
16,733
749
667
1,257
1,25766774916,73316,055451664921414-825,1002,3492,9221,6502,0702,4601,93221434,5471891461832904323962062764073772062833742922642,3843182521718229827780819225519431294532409243772843893493937256868461,044711760774344000
   > Long-term Assets 
0
0
0
3,381
3,451
3,579
3,560
3,665
3,796
3,852
3,927
0
3,905
3,863
3,821
3,036
3,048
3,082
2,978
2,864
2,864
2,810
2,771
2,719
2,690
2,678
2,682
2,581
2,536
2,480
2,402
2,373
2,373
2,215
27,942
25,574
27,694
27,440
27,714
27,438
27,051
27,017
27,048
26,798
26,561
26,334
26,088
25,778
32,803
32,377
31,916
3,657
32,441
34,524
35,494
42,371
53,922
58,952
55,054
54,336
54,336
13,565
17,293
14,948
14,656
14,323
14,015
13,062
12,812
13,412
13,41212,81213,06214,01514,32314,65614,94817,29313,56554,33654,33655,05458,95253,92242,37135,49434,52432,4413,65731,91632,37732,80325,77826,08826,33426,56126,79827,04827,01727,05127,43827,71427,44027,69425,57427,9422,2152,3732,3732,4022,4802,5362,5812,6822,6782,6902,7192,7712,8102,8642,8642,9783,0823,0483,0363,8213,8633,90503,9273,8523,7963,6653,5603,5793,4513,381000
       Property Plant Equipment 
0
0
0
14
13
17
16
15
14
13
12
11
11
9
8
8
7
6
6
2
2
4
5
6
5
5
7
6
20
17
14
13
13
14
25,775
25,574
25,574
25,453
25,794
25,589
25,268
25,289
25,335
25,152
24,981
24,812
24,641
24,380
31,456
31,104
30,688
3,657
31,273
31,796
32,787
34,739
39,003
38,281
39,818
41,755
41,755
7,864
7,822
7,551
7,242
6,930
6,605
6,372
6,099
5,824
5,8246,0996,3726,6056,9307,2427,5517,8227,86441,75541,75539,81838,28139,00334,73932,78731,79631,2733,65730,68831,10431,45624,38024,64124,81224,98125,15225,33525,28925,26825,58925,79425,45325,57425,57425,77514131314172067556542266788911111213141516171314000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,760
1,760
1,760
0
0
0
0
0
0
0
0
0
0
0
000000000001,7601,7601,76000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
3,367
3,437
3,561
3,543
3,650
3,782
3,839
3,915
3,894
3,894
3,854
3,813
3,027
3,041
2,990
2,972
2,862
2,862
2,805
2,766
2,713
2,685
2,673
2,675
2,575
2,516
2,463
2,388
2,360
2,360
2,201
2,139
2,092
2,092
1,960
1,895
1,823
1,757
1,702
1,687
1,620
1,554
1,498
1,423
1,374
1,323
1,249
1,204
1,144
1,144
1,185
1,146
952
5,164
5,041
4,919
4,851
4,851
5,398
5,393
5,388
5,383
5,378
5,373
5,368
5,363
6,108
6,1085,3635,3685,3735,3785,3835,3885,3935,3984,8514,8514,9195,0415,1649521,1461,1851,1441,1441,2041,2491,3231,3741,4231,4981,5541,6201,6871,7021,7571,8231,8951,9602,0922,0922,1392,2012,3602,3602,3882,4632,5162,5752,6752,6732,6852,7132,7662,8052,8622,8622,9722,9903,0413,0273,8133,8543,8943,8943,9153,8393,7823,6503,5433,5613,4373,367000
       Other Assets 
0
0
0
0
3,438
3,562
3,544
3,649
3,782
3,839
3,915
3,893
3,872
3,853
3,813
3,027
3,040
3,076
2,972
2,863
2,838
2,806
2,765
2,713
2,685
2,673
2,675
2,575
2,516
2,463
2,388
2,360
2,284
2,201
2,167
2,120
2,049
1,987
1,920
1,849
1,783
1,728
26
26
26
24
24
24
24
24
24
24
24
1,543
1,561
6,680
7,995
13,870
8,557
7,730
7,719
303
0
2,009
0
0
0
0
0
0
0000002,00903037,7197,7308,55713,8707,9956,6801,5611,54324242424242424242626261,7281,7831,8491,9201,9872,0492,1202,1672,2012,2842,3602,3882,4632,5162,5752,6752,6732,6852,7132,7652,8062,8382,8632,9723,0763,0403,0273,8133,8533,8723,8933,9153,8393,7823,6493,5443,5623,4380000
> Total Liabilities 
0
0
0
9,752
1,073
521
369
542
777
2,706
1,879
3,854
3,854
8,241
7,421
7,139
4,691
4,715
3,801
3,596
3,596
3,088
2,684
4,286
1,653
1,664
1,213
395
1,218
1,475
1,254
1,263
1,263
1,538
27,749
27,556
27,556
27,042
27,750
27,095
27,140
27,029
26,882
26,919
29,868
29,225
28,772
28,129
37,104
36,904
38,263
37,582
37,582
38,085
37,867
38,400
43,214
35,850
35,990
35,921
35,921
32,977
26,997
25,826
24,469
24,825
25,291
7,410
6,763
7,802
7,8026,7637,41025,29124,82524,46925,82626,99732,97735,92135,92135,99035,85043,21438,40037,86738,08537,58237,58238,26336,90437,10428,12928,77229,22529,86826,91926,88227,02927,14027,09527,75027,04227,55627,55627,7491,5381,2631,2631,2541,4751,2183951,2131,6641,6534,2862,6843,0883,5963,5963,8014,7154,6917,1397,4218,2413,8543,8541,8792,7067775423695211,0739,752000
   > Total Current Liabilities 
0
0
0
1,929
1,073
521
369
542
777
2,706
1,879
3,854
3,854
8,241
1,282
7,139
4,691
4,715
3,801
3,596
3,596
3,088
2,684
4,286
1,653
1,664
1,213
395
1,218
1,475
1,254
1,263
1,263
1,538
2,441
2,291
2,291
1,867
2,621
2,013
2,106
2,044
1,947
2,035
5,036
4,445
4,046
3,458
4,869
4,744
6,179
5,236
5,236
6,102
6,067
6,645
8,098
8,346
8,281
30,436
30,436
27,775
22,276
21,582
20,708
21,553
21,426
3,840
3,469
4,709
4,7093,4693,84021,42621,55320,70821,58222,27627,77530,43630,4368,2818,3468,0986,6456,0676,1025,2365,2366,1794,7444,8693,4584,0464,4455,0362,0351,9472,0442,1062,0132,6211,8672,2912,2912,4411,5381,2631,2631,2541,4751,2183951,2131,6641,6534,2862,6843,0883,5963,5963,8014,7154,6917,1391,2828,2413,8543,8541,8792,7067775423695211,0731,929000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,483
397
1,315
520
761
126
17
0
0
0
0
0
0
0
0
0
0
0
167
25,435
170
176
180
183
187
190
194
197
201
205
209
213
139
216
1,491
261
562
777
884
967
521
205
55
0
22,308
16,585
14,342
13,598
13,303
13,352
13,579
953
955
667
66795595313,57913,35213,30313,59814,34216,58522,3080552055219678847775622611,49121613921320920520119719419018718318017617025,43516700000000000171267615201,3153971,4830000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,435
0
176
180
25,265
25,221
25,175
25,129
25,081
0
0
0
0
0
0
1,196
261
362
465
566
600
0
0
0
22,161
22,201
16,011
13,700
12,937
12,625
12,655
12,863
218
227
237
23722721812,86312,65512,62512,93713,70016,01122,20122,1610006005664653622611,19600000025,08125,12925,17525,22125,265180176025,43500000000000000000000000000000000000
       Accounts payable 
0
0
0
506
148
373
150
112
777
1,965
1,080
2,007
2,007
1,970
1,102
2,895
2,981
4,041
2,182
3,076
2,846
2,711
2,416
2,401
1,313
1,245
1,118
297
516
984
815
1,263
1,104
1,334
1,551
2,097
1,177
731
1,391
749
596
701
939
790
692
662
722
1,001
661
442
547
2,864
1,759
2,409
1,631
2,254
2,292
2,739
5,279
4,264
4,264
4,002
2,013
1,849
1,911
1,859
1,228
358
855
614
6148553581,2281,8591,9111,8492,0134,0024,2644,2645,2792,7392,2922,2541,6312,4091,7592,8645474426611,0017226626927909397015967491,3917311,1772,0971,5511,3341,1041,2638159845162971,1181,2451,3132,4012,4162,7112,8463,0762,1824,0412,9812,8951,1021,9702,0072,0071,0801,965777112150373148506000
       Other Current Liabilities 
0
0
0
1,423
926
148
218
430
777
741
799
1,847
1,847
6,271
181
4,244
1,710
673
1,619
750
750
377
267
1,885
340
419
95
98
702
491
405
159
159
188
647
24
920
905
957
924
1,047
1,130
746
577
1,125
1,052
1,074
965
1,175
1,053
1,135
34,118
1,105
1,683
2,666
3,001
5,191
5,342
2,939
100
3,764
7,100
5,921
1,941
1,939
6,342
6,444
2,329
1,441
3,428
3,4281,4412,3296,4446,3421,9391,9415,9217,1003,7641002,9395,3425,1913,0012,6661,6831,10534,1181,1351,0531,1759651,0741,0521,1255777461,1301,0479249579059202464718815915940549170298954193401,8852673777507501,6196731,7104,2441816,2711,8471,8477997417774302181489261,423000
   > Long-term Liabilities 
0
0
0
7,823
7,823
0
0
0
0
0
0
0
0
0
6,139
0
0
0
0
0
1,001
377
267
0
0
419
95
0
0
0
1,220
0
0
1,522
25,308
0
25,265
25,175
25,129
25,082
25,034
24,985
24,935
24,884
24,832
24,780
24,726
24,671
32,235
32,160
32,084
32,346
32,346
31,983
31,800
31,755
35,116
27,504
27,709
5,485
5,485
5,202
4,721
4,244
3,761
3,272
3,865
3,570
3,294
3,093
3,0933,2943,5703,8653,2723,7614,2444,7215,2025,4855,48527,70927,50435,11631,75531,80031,98332,34632,34632,08432,16032,23524,67124,72624,78024,83224,88424,93524,98525,03425,08225,12925,17525,265025,3081,522001,22000095419002673771,001000006,1390000000007,8237,823000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,884
24,832
24,780
24,726
24,671
32,235
32,160
32,084
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000032,08432,16032,23524,67124,72624,78024,83224,8840000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,065
0
527
0
0
0
0
0
0
00000052701,0650000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34
0
0
16
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000160034000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-6,203
5,744
5,180
4,859
4,388
6,673
5,206
3,598
1,076
1,076
2,175
628
197
886
305
6,855
6,169
6,169
3,717
2,298
5,068
5,682
7,954
7,001
6,099
5,439
9,567
10,192
11,231
11,231
7,878
8,265
9,937
9,937
4,153
12,946
8,914
6,293
7,812
4,154
16,166
13,031
11,082
6,907
2,463
-1,933
-511
3,966
56,618
56,618
107,335
104,845
108,585
100,543
90,598
79,380
63,485
63,485
18,823
17,389
15,381
13,209
9,197
24,863
21,324
17,754
13,895
13,89517,75421,32424,8639,19713,20915,38117,38918,82363,48563,48579,38090,598100,543108,585104,845107,33556,61856,6183,966-511-1,9332,4636,90711,08213,03116,1664,1547,8126,2938,91412,9464,1539,9379,9378,2657,87811,23111,23110,1929,5675,4396,0997,0017,9545,6825,0682,2983,7176,1696,1696,8553058861976282,1751,0761,0763,5985,2066,6734,3884,8595,1805,744-6,203000
   Common Stock
0
0
0
0
23
23
23
23
28
28
28
28
28
36
32
32
32
32
48
48
48
48
48
57
57
544
66
66
68
72
74
77
77
77
83
89
89
89
89
89
93
115
116
16
18
19
20
20
24
55
107
140
140
212
216
217
217
218
218
9
9
12
16
20
28
30
9
9
9
9
9999302820161299218218217217216212140140107552420201918161161159389898989898377777774726866665445757484848484832323232362828282828232323230000
   Retained Earnings Total Equity0000000000000-182,5660-173,743-166,082-157,953-150,420-146,882-135,606-110,284-105,821-101,318-97,095-92,626-88,228-83,810-79,848-75,949-72,123-67,794-63,881-60,652-57,591-54,914-51,878-49,632-47,827-45,942-44,265-42,612-41,202-40,060-38,781-37,157-37,536-36,218-34,460-33,389-31,338-29,975-26,876-25,2790000000000000000
   Accumulated Other Comprehensive Income 00000000-167-2130-194-91-64-63-70-53-33-6,626-33-31-32-31-31-30-31-30-29-29-29-29-29-29-29-605-31-33-250-26-14-3000-21-20-200000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,133
27,150
36,782
37,459
37,913
38,129
38,468
42,547
42,782
46,191
46,995
47,235
47,986
53,774
56,086
59,006
59,398
59,712
63,127
67,468
67,733
67,974
80,680
80,977
82,178
87,574
87,877
104,408
105,670
108,188
108,236
108,295
108,359
135,071
150,774
206,931
237,867
273,258
278,442
0
282,956
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000282,9560278,442273,258237,867206,931150,774135,071108,359108,295108,236108,188105,670104,40887,87787,57482,17880,97780,68067,97467,73367,46863,12759,71259,39859,00656,08653,77447,98647,23546,99546,19142,78242,54738,46838,12937,91337,45936,78227,15026,1330000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
575
13,041
13,065
13,045
13,073
15,920
14,499
14,507
0
14,567
23,187
24,675
25,826
26,133
27,150
36,782
0
37,459
38,129
38,488
42,567
42,803
46,191
46,995
47,235
47,986
53,774
56,086
-25
59,006
59,712
63,127
-29
67,468
67,974
80,680
80,977
82,178
87,574
87,877
104,408
105,670
108,188
108,236
108,295
108,359
135,071
150,774
-33
206,931
273,258
278,442
282,058
282,938
284,957
286,232
-213
287,619
294,591
300,280
304,301
307,867
312,064
330,923
335,162
335,581
336,086
336,086335,581335,162330,923312,064307,867304,301300,280294,591287,619-213286,232284,957282,938282,058278,442273,258206,931-33150,774135,071108,359108,295108,236108,188105,670104,40887,87787,57482,17880,97780,68067,97467,468-2963,12759,71259,006-2556,08653,77447,98647,23546,99546,19142,80342,56738,48838,12937,459036,78227,15026,13325,82624,67523,18714,567014,50714,49915,92013,07313,04513,06513,041575000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue225
Cost of Revenue-1,250
Gross Profit225-1,025
 
Operating Income (+$)
Gross Profit225
Operating Expense-16,859
Operating Income-16,634-16,634
 
Operating Expense (+$)
Research Development5,185
Selling General Administrative11,674
Selling And Marketing Expenses0
Operating Expense16,85916,859
 
Net Interest Income (+$)
Interest Income363
Interest Expense-172
Other Finance Cost-0
Net Interest Income191
 
Pretax Income (+$)
Operating Income-16,634
Net Interest Income191
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-15,443-17,825
EBIT - interestExpense = -15,443
-15,271
-24,735
Interest Expense172
Earnings Before Interest and Taxes (EBIT)-15,271-15,271
Earnings Before Interest and Taxes (EBITDA)-14,021
 
After tax Income (+$)
Income Before Tax-15,443
Tax Provision-0
Net Income From Continuing Ops-15,443-15,443
Net Income-24,907
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses16,859
Total Other Income/Expenses Net1,191-191
 

Technical Analysis of iBio, Inc. Common Stock
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of iBio, Inc. Common Stock. The general trend of iBio, Inc. Common Stock is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine iBio, Inc. Common Stock's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of iBio, Inc. Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.8908 < 7.834 < 8.568.

The bearish price targets are: 4.98 > 3.15 > 3.15.

Tweet this
iBio, Inc. Common Stock Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of iBio, Inc. Common Stock. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

iBio, Inc. Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of iBio, Inc. Common Stock. The current macd is 0.74415267.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the iBio, Inc. Common Stock price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for iBio, Inc. Common Stock. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the iBio, Inc. Common Stock price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
iBio, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartiBio, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of iBio, Inc. Common Stock. The current adx is 39.49.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy iBio, Inc. Common Stock shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
iBio, Inc. Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of iBio, Inc. Common Stock. The current sar is 4.71317419.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
iBio, Inc. Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of iBio, Inc. Common Stock. The current rsi is 63.23. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
iBio, Inc. Common Stock Daily Relative Strength Index (RSI) ChartiBio, Inc. Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of iBio, Inc. Common Stock. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the iBio, Inc. Common Stock price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
iBio, Inc. Common Stock Daily Stochastic Oscillator ChartiBio, Inc. Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of iBio, Inc. Common Stock. The current cci is 69.75.

iBio, Inc. Common Stock Daily Commodity Channel Index (CCI) ChartiBio, Inc. Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of iBio, Inc. Common Stock. The current cmo is 21.23.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
iBio, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) ChartiBio, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of iBio, Inc. Common Stock. The current willr is -38.14957072.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that iBio, Inc. Common Stock is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
iBio, Inc. Common Stock Daily Williams %R ChartiBio, Inc. Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of iBio, Inc. Common Stock.

iBio, Inc. Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of iBio, Inc. Common Stock. The current atr is 0.62646241.

iBio, Inc. Common Stock Daily Average True Range (ATR) ChartiBio, Inc. Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of iBio, Inc. Common Stock. The current obv is 220,657,742.

iBio, Inc. Common Stock Daily On-Balance Volume (OBV) ChartiBio, Inc. Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of iBio, Inc. Common Stock. The current mfi is 76.74.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
iBio, Inc. Common Stock Daily Money Flow Index (MFI) ChartiBio, Inc. Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for iBio, Inc. Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

iBio, Inc. Common Stock Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of iBio, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.233
Ma 20Greater thanMa 504.495
Ma 50Greater thanMa 1003.500
Ma 100Greater thanMa 2003.049
OpenGreater thanClose5.580
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of iBio, Inc. Common Stock with someone you think should read this too:
  • Are you bullish or bearish on iBio, Inc. Common Stock? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about iBio, Inc. Common Stock? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about iBio, Inc. Common Stock

I send you an email if I find something interesting about iBio, Inc. Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about iBio, Inc. Common Stock.

Receive notifications about iBio, Inc. Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.